An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors
Molecular Diversity · 2025-10 · 29 (5) · 4765-4785
DOI: 10.1007/s11030-024-11016-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diversity, online erschienen am 27.11.2024. Verfasst von Mohamed T M Nemr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Eini Street 11562, Cairo, Egypt. mohamed.nemr@pharma.cu.e…. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Phosphodiesterase enzyme 5 (PDE5) inhibitors have emerged as one of the leading molecules for the treatment of erectile dysfunction (ED). PDE5 inhibitors are categorized structurally into several classes. PDE5 inhibitors have been a multidisciplinary endeavor that attracts the attention of researchers because of their multiple pharmaceutical applications. Beyond their action on ED, PDE5 inhibitors are widely used in treatment of benign prostatic hypertrophy (BPH), Eisenmenger’s syndrome, Raynaud’s Disease, Intrauterine growth retardation (IUGR), Mountain sickness, Bladder pain syndrome/interstitial cystitis (BPS/IC), pulmonary arterial hypertension and type II diabetes (insulin resistance). In addition, PDE5 inhibitors also show promising antiproliferative activity, anti-Alzheimer and COX-1/COX-2 inhibitory activity (anti-inflammatory). Pharmacokinetics, Pharmacogenetics and toxicity of PDE5 inhibitors were finally explored. The diverse therapeutic applications, the high feasibility of structural modification and the appropriate pharmacokinetic properties of PDE5 inhibitors have motivated researchers to develop new scaffolds that have been either under clinical trials or approved by FDA and utilize them to overcome some recent global concerns, such as COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Eini Street 11562, Cairo, Egypt. mohamed.nemr@pharma.cu.edu.eg.
- Department of Chemistry, College of Wooster, Wooster, OH, 44691, USA.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
- Faculty of Pharmacy, Alamein International University (AIU), Alamein City, Alamein City, 5060310, Egypt.
- Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia, Egypt.
- Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia, Egypt. yaseen.elshaier@fop.usc.edu.eg.
Förderung
- Cairo University
Zitieren
APA
Nemr, M. T. M., Abdelaziz, M. A., Teleb, M., Elmasry, A. E., & Elshaier, Y. A. A. M. (2025). An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors. Molecular Diversity, 29(5), 4765-4785. https://doi.org/10.1007/s11030-024-11016-2
Vancouver
Nemr MTM, Abdelaziz MA, Teleb M, Elmasry AE, Elshaier YAAM. An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors. Molecular Diversity. 2025;29(5):4765-4785. doi:10.1007/s11030-024-11016-2
BibTeX
@article{Nemr2025,
author = {Nemr, Mohamed T M and Abdelaziz, Mostafa A and Teleb, Mohamed and Elmasry, Ahmed E and Elshaier, Yaseen A A M},
title = {An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors},
journal = {Molecular Diversity},
year = {2025},
volume = {29},
number = {5},
pages = {4765--4785},
doi = {10.1007/s11030-024-11016-2}
}
EUVIMED